Management of transformed accelerated phase chronic myeloid leukemia (AP CML)

This algorithm describes management of transformed AP CML (ie, AP CML that arose while the patient was receiving a TKI); importantly, management of transformed AP CML differs from that of de novo CML (ie, patients whose initial presentation is AP CML and who have not received prior TKI therapy).
Refer to related UpToDate material for diagnostic criteria for transformed CML AP, selection of a TKI, and eligibility for allogeneic HCT.